

CITATION REPORT

List of articles citing

TGF- β : an emerging player in drug resistance

DOI: 10.4161/cc.26034
Cell Cycle, 2013, 12, 2960-8.

Source: <https://exaly.com/paper-pdf/56777262/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
105	A crucial role for the phosphorylation of STRAP at Ser(188) by MPK38 in STRAP-dependent cell death through ASK1, TGF- β p53, and PI3K/PDK1 signaling pathways. <i>Cell Cycle</i> , 2014 , 13, 3357-74	4.7	18
104	Resistance to targeted cancer drugs through hepatocyte growth factor signaling. <i>Cell Cycle</i> , 2014 , 13, 3808-17	4.7	15
103	Finding effective cancer therapies through loss of function genetic screens. 2014 , 24, 23-9		14
102	Drug resistance to targeted therapies: dJlvu all over again. 2014 , 8, 1067-83		137
101	Treatment Individualization in Colorectal Cancer. 2015 , 11, 335-344		13
100	The TGF- β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells. 2016 , 7, 22077-91		39
99	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. 2016 , 7, 20810-24		63
98	Regulation of Natural Killer Cell Function by STAT3. 2016 , 7, 128		48
97	TGF β signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. 2016 , 8, 745-60		90
96	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. 2016 , 165, 317-30		57
95	Ly6E/K Signaling to TGF β Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. 2016 , 76, 3376-86		51
94	Crosstalk between TGF- β signaling and miRNAs in breast cancer metastasis. 2016 , 37, 10011-9		28
93	Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis. 2016 , 7, e2254		91
92	Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. 2016 , 19, 53-62		39
91	Targeting TGF- β signaling in Cancer. 2017 , 3, 56-71		444
90	Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF- β -dependent activation of Smad/ERK signaling. 2017 , 8, e2885		27
89	Node-based learning of differential networks from multi-platform gene expression data. 2017 , 129, 41-49		11

88	CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. 2017 , 28, 1032-1035	32
87	A83-01 inhibits TGF- β -induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. 2017 , 163, 449-460	33
86	EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line. 2017 , 143, 2211-2219	12
85	A molecular signature for anastasis, recovery from the brink of apoptotic cell death. 2017 , 216, 3355-3368	62
84	Hedyotis diffusa Willd suppresses metastasis in 5-fluorouracil-resistant colorectal cancer cells by regulating the TGF- β -signaling pathway. 2017 , 16, 7752-7758	17
83	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. 2017 , 10, 5491-5524	34
82	c-Jun/AP-1 overexpression reprograms ER β -signaling related to tamoxifen response in ER β -positive breast cancer. 2018 , 37, 2586-2600	22
81	MicroRNA-140 Inhibits the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer. 2018 , 10, 426-437	35
80	Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. 2018 , 275, 67-77	30
79	The Dual Role of Bone Morphogenetic Proteins in Cancer. 2018 , 8, 1-13	90
78	TGF β -pathway inhibition in the treatment of non-small cell lung cancer. 2018 , 184, 112-130	46
77	Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma. 2018 , 19,	7
76	A novel mechanism of plasminogen activation in epithelial and mesenchymal cells. 2018 , 8, 14091	14
75	Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF- β -pathway. 2018 , 8, 4733-4749	35
74	Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF- κ B/survivin signaling pathway. 2018 , 104, 729-737	6
73	The Dynamic Roles of TGF- β -Signalling in EBV-Associated Cancers. 2018 , 10,	15
72	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. 2018 , 10,	23
71	Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor. 2018 , 102, 128-137	15

70	Cell signaling and cancer: a mechanistic insight into drug resistance. 2019 , 46, 5645-5659	31
69	Recent Progress on Circular RNA Research in Acute Myeloid Leukemia. 2019 , 9, 1108	35
68	Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study. 2019 , 173, 169-175	3
67	Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. 2019 , 21, 778-790	12
66	Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. 2019 , 19, 421	1
65	MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer. 2019 , 84, 427-439	15
64	Screening candidate microRNA-mRNA network for predicting the response to chemoresistance in osteosarcoma by bioinformatics analysis. 2019 , 120, 16798-16810	8
63	Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy. 2019 , 62, 873-884	3
62	Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer. 2019 , 11,	20
61	CAFs and TGF- β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. 2019 , 11,	55
60	High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype. 2019 , 2019, 5231269	3
59	Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. 2019 , 10, 1693	65
58	An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance. 2019 , 8,	12
57	TGF- β -Induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR. <i>Cell Cycle</i> , 2019 , 18, 3589-3602	4-7 32
56	Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. 2019 , 11, 35-51	59
55	Role of the transforming growth factor- β signaling pathway in the pathogenesis of colorectal cancer. 2019 , 120, 8899-8907	17
54	CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis. 2019 , 70, 42-54.e3	78
53	Activated Wnt/ β Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer. 2020 , 254, 116816	5

52	TGF β -SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. 2020 , 33, 108221	9
51	TGF β Causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. 2020 , 10, 7656-7670	13
50	Obg-like ATPase 1 inhibited oral carcinoma cell metastasis through TGF β /SMAD2 axis in vitro. 2020 , 21, 65	2
49	miR-552: an important post-transcriptional regulator that affects human cancer. 2020 , 11, 6226-6233	4
48	Effects of different levels of TGF β expression and tumor cell necrosis rates in osteosarcoma on the chemotherapy resistance of osteosarcoma. 2020 , 23, 100299	6
47	Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes. 2020 , 24, 340-351	13
46	Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. 2020 , 24, 314-339	14
45	Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor- β signaling and radioiodine resistance. 2020 , 295, 10726-10740	4
44	Long non-coding RNA in bladder cancer. 2020 , 503, 113-121	19
43	The prognostic role of soluble transforming growth factor- β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer. 2021 , 41, 388-395	2
42	Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development. 2021 , 25, 81-92	7
41	Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy. 2021 , 329, 1023-1036	10
40	H3K27me3 is a determinant of chemotolerance in triple-negative breast cancer.	1
39	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. 2021 , 9, 641469	30
38	Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF β Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p. 2021 , 79, 757-767	2
37	GARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment. 2021 , 10,	3
36	Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8. 2021 , 402, 1247-1256	2
35	Estimating Intraclonal Heterogeneity and Subpopulation Changes from Perturbational Bulk Gene Expression Profiles in LINCS L1000 CMap by Premnas.	0

34	Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF- β -mediated transcription and sensitize the gastric cancer cells to doxorubicin. 2021 , 74, 105152	6
33	Penetration Cascade of Size Switchable Nanosystem in Desmoplastic Stroma for Improved Pancreatic Cancer Therapy. 2021 , 15, 14149-14161	10
32	TGF- β -Induced TMEPAI Promotes Epithelial-Mesenchymal Transition in Doxorubicin-Treated Triple-Negative Breast Cancer Cells via SMAD3 and PI3K/AKT Pathway Alteration. 2021 , 13, 529-538	0
31	Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGF β signaling loop in esophageal squamous cell carcinoma. 2017 , 56, 1150-1163	42
30	Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. 2018 , 118, 106-116	17
29	A Molecular Signature for Anastasis, Recovery from the Brink of Apoptotic Cell Death.	4
28	5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes. 2020 , 111, 3142-3154	62
27	TAB3 upregulates Survivin expression to promote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex. 2017 , 8, 106565-106576	7
26	Drug resistance and combating drug resistance in cancer. 2019 , 2, 141-160	138
25	Exploiting Canonical TGF β Signaling in Cancer Treatment. 2021 ,	1
24	An integrative systems biology and experimental approach identifies convergence of epithelial plasticity, metabolism, and autophagy to promote chemoresistance.	1
23	Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors. 2020 , 16, e1009176	6
22	TGF- β protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH/HIF1 α -dependent manner. 2021 , 21, 1200	0
21	Regulatory role of the transforming growth factor- β signaling pathway in the drug resistance of gastrointestinal cancers. 2021 , 13, 1648-1667	0
20	TGF- β Signaling and Resistance to Cancer Therapy.. 2021 , 9, 786728	9
19	Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer.. 2022 , 60, 100811	3
18	Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors.. 2022 , 7, 3293-3311	0
17	Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers.. 2022 , 21, 15330338211068965	0

16	Decoding mechanism of action and susceptibility to drug candidates from integrated transcriptome and chromatin state.	
15	The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF- β and PD-L1 Pathways.. 2022 , 12, 814169	0
14	Runx2 deficiency in osteoblasts promotes myeloma resistance to bortezomib by increasing TSP-1-dependent TGF- β activation and suppressing immunity in bone marrow.. 2021 ,	1
13	EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures.. 2022 , 14,	1
12	Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. 2022 , 14, 2928	4
11	Estimating intraclonal heterogeneity and subpopulation changes from bulk expression profiles in CMap. 2022 , 5, e202101299	0
10	Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review). 2022 , 61,	0
9	Decoding mechanism of action and sensitivity to drug candidates from integrated transcriptome and chromatin state. 11,	0
8	Loss of SNAI1 induces cellular plasticity in invasive triple-negative breast cancer cells. 2022 , 13,	0
7	Importance of TGF- β in Cancer and Nematode Infection and Their InteractionOpinion. 2022 , 12, 1572	1
6	Mechanism and function of miR-140 in human cancers: A review and in silico study. 2023 , 241, 154265	1
5	Epithelial TGF- β engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. 2022 , 13,	0
4	The ceRNA network regulates epithelial-mesenchymal transition in colorectal cancer. 2023 , 9, e14143	0
3	High expression of LY6E is an independent prognostic factor of colorectal cancer patients. 2023 , 49,	0
2	Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. 29, 1911-1941	0
1	TGF- β Mediated Drug Resistance in Solid Cancer. 2023 ,	0